首页> 外文期刊>Experimental and clinical transplantation >Synergistic Effect of Ischemic Preconditioning and Antithrombin in Ischemia-Reperfusion Injury
【24h】

Synergistic Effect of Ischemic Preconditioning and Antithrombin in Ischemia-Reperfusion Injury

机译:缺血预处理与抗凝血酶在缺血再灌注损伤中的协同作用

获取原文
           

摘要

Objectives: Our study aimed to determine whether antithrombin plays a synergistic role in accentuating the effects of intestinal ischemic preconditioning. Materials and Methods: Fifty rats were randomly allocated to 5 groups (10 rats/group) as follows: sham treatment (group 1); ischemia-reperfusion (group 2); ischemic preconditioning followed by ischemia-reperfusion (group 3); antithrombin + ischemia-reper-fusion, similar to group 2 but including antithrombin administration (group 4); and antithrombin + ischemic preconditioning, similar to group 3 but including antithrombin administration (group 5). Blood samples and liver specimens were obtained for measurement of cytokines, myeloperoxidase, and malondialdehyde. Liver biopsies were examined by electron microscopy. Results: Intestinal ischemia-reperfusion induced a remote hepatic inflammatory response as evidenced by the striking increase of proinflammatory cytokines, myeloperoxidase, and malondialdehyde. Tumor necro-sis factor-α levels in group 5 (12.48 ± 0.7 pg/mL) were significantly lower than in group 3 (13.64 ± 0.78 pg/mL; P = .014). Mean interleukin 1β was lower in group 5 (9.52 ± 0.67pg/mL) than in group 3 (11.05 ± 1.9 pg/mL; P > .99). Mean interleukin 6 was also significantly lower in group 5 (17.13 ± 0.54 pg/mL) than in group 3 (23.82 ± 1 pg/mL; P P = .025). However, malondialdehyde levels did not significantly improve in group 5 (4.55 ± 0.46 μmol) versus group 3 (5.17 ± 0.61 μmol; P = .286). Tumor necrosis factor-α, interleukin 6, and myeloperoxidase findings show that antithrombin administration further attenuated the inflammatory response caused by ischemia-reperfusion, suggesting a synergistic effect with ischemic preconditioning. These findings were confirmed by electron microscopy. Conclusions: The addition of antithrombin to ischemic preconditioning may act to attenuate or prevent damage from ischemia-reperfusion injury by inhi-biting the release of cytokines and neutrophil infiltration.
机译:目的:我们的研究旨在确定抗凝血酶是否在增强肠道缺血预处理的作用中发挥协同作用。材料与方法:50只大鼠随机分为5组,每组10只。缺血再灌注(第2组);缺血预处理,然后进行缺血再灌注(第3组);抗凝血酶+缺血再灌注,类似于第2组,但包括抗凝血酶给药(第4组);和抗凝血酶+缺血预处理,类似于第3组,但包括抗凝血酶给药(第5组)。获得血液样本和肝脏样本以测量细胞因子,髓过氧化物酶和丙二醛。通过电子显微镜检查肝活检。结果:肠缺血再灌注引起了远处的肝炎性反应,如促炎性细胞因子,髓过氧化物酶和丙二醛的显着增加所证明。第5组的肿瘤坏死因子-α水平(12.48±0.7 pg / mL)显着低于第3组(13.64±0.78 pg / mL; P = .014)。第5组的平均白介素1β含量(9.52±0.67pg / mL)低于第3组的(11.05±1.9 pg / mL; P> .99)。第5组的平均白介素6也显着低于第3组(23.82±1 pg / mL; P P = .025),在第5组(17.13±0.54 pg / mL)。但是,与第3组(5.17±0.61μmol; P = 0.286)相比,第5组(4.55±0.46μmol)的丙二醛水平没有显着改善。肿瘤坏死因子-α,白介素6和髓过氧化物酶的发现表明,抗凝血酶给药可进一步减轻缺血-再灌注引起的炎症反应,表明与缺血预处理具有协同作用。这些发现通过电子显微镜证实。结论:在缺血预处理中添加抗凝血酶可能通过抑制细胞因子的释放和中性粒细胞浸润来减轻或预防缺血再灌注损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号